Croda strengthens Asian footprint with new facility in Dahej

INDIA – Croda International Plc has launched a new greenfield manufacturing plant in Dahej, India, to boost its presence in the region and address escalating demand for its speciality ingredients across Asia.​

Situated in Gujarat with excellent logistics links, the Dahej site caters to domestic clients and select exports while boosting supply for consumer care, life sciences, and industrial specialities sectors. 

This major investment enhances Croda’s responsiveness to customer needs and fuels expansion in high-value markets.

Steve Foots, Group Chief Executive, said, “This investment in Dahej is a clear demonstration of Croda’s commitment to the Indian market.”

“The site combines strong sustainability credentials with high safety and operational standards, positioning us to better serve customers in India and beyond. “

He added, “We see significant long-term growth potential in the region and this facility provides a strong platform to support that ambition.” 

The plant embodies a “Built Green, Built Smart, Built for the Future” approach, relying on renewable energy and fuels to slash Scope 1 and 2 emissions. 

It incorporates upcoming Zero Liquid Discharge systems, RSPO-certified oleochemicals, full compliance with plastic recycling standards, and advanced technologies such as alkoxylation and pastillation.

Advanced systems, quality controls, and rigorous safety protocols ensure dependable production, highlighted by over 5 million safe construction hours under Croda’s “Safety First Always” principle. 

The facility marks Croda India’s first EXCiPACT-certified site and runs carbon-neutral operations for Scopes 1 and 2.

Packaging operations are entirely led by women, with a target of 30% female staff overall, underscoring Croda’s diversity focus. 

Croda FY25 highlights

Croda International Plc recently released its full-year results for the period ended December 31, 2025, highlighting early progress in its strategy to boost earnings and enhance returns.

Sales grew 4.4% to £1,699.4 million (USD 2.27 billion), or 6.6% at constant currency, fueled by expansion in Consumer Care and Life Sciences segments. 

Adjusted operating profit increased 5.6% to £295.3 million (USD 394.3 million), lifting the adjusted operating margin to 17.4%. 

Statutory net income stood at £62 million (USD 83.4 million), with basic earnings per share at £0.444 (USD 0.592), down from prior year figures amid transitional challenges.

The Group outlined a three-year financial framework to sustain growth through smart science-driven ingredients for personal care, health, and industrial applications. 

This includes targeted actions to improve operational efficiency and capital returns.

Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.